IDEAS home Printed from https://ideas.repec.org/a/plo/pone00/0307086.html
   My bibliography  Save this article

Determining the societal value of a prospective drug for ME/CFS in Germany

Author

Listed:
  • Afschin Gandjour

Abstract

Background: Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) imposes a substantial societal and economic burden. The aim of this study is to ascertain the optimal level of public research and development (R&D) investment in Germany for a prospective drug, given the pressing need for effective treatments. Methods: This study calculates the societal value from a German perspective by integrating health and economic outcomes in the context of public R&D investment for ME/CFS. It considers factors such as direct medical costs, productivity loss, and the effectiveness of a prospective drug. Results: The anticipated introduction of a prospective drug is estimated to yield a quality-adjusted life year (QALY) gain of approximately 29,000 and a societal value of about €2.6 billion. The optimal R&D investment in Germany is estimated at €676 million, which represents about a quarter of the total investment required to bring a significant drug to market, considering diminishing returns and market constraints. Results were confirmed in the sensitivity analysis. Conclusions: The study concludes that a coordinated international approach is imperative to address the funding and market size limitations effectively in developing treatments for ME/CFS and to realize the substantial societal and economic benefits.

Suggested Citation

  • Afschin Gandjour, 2024. "Determining the societal value of a prospective drug for ME/CFS in Germany," PLOS ONE, Public Library of Science, vol. 19(7), pages 1-11, July.
    • Handle: RePEc:plo:pone00:0307086
    DOI: 10.1371/journal.pone.0307086
    as

    Download full text from publisher

    File URL: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0307086
    Download Restriction: no
    File URL: https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0307086&type=printable
    Download Restriction: no
    File URL: https://libkey.io/10.1371/journal.pone.0307086?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Gandjour, Afschin, 2018. "Underuse of innovative medicines in Germany: A justification for government intervention?," Health Policy, Elsevier, vol. 122(12), pages 1283-1286.
    2. Michael Falk Hvidberg & Louise Schouborg Brinth & Anne V Olesen & Karin D Petersen & Lars Ehlers, 2015. "The Health-Related Quality of Life for Patients with Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME/CFS)," PLOS ONE, Public Library of Science, vol. 10(7), pages 1-16, July.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Scoles, Brooke & Nicodemo, Catia, 2022. "Doctors’ attitudes toward specific medical conditions," Journal of Economic Behavior & Organization, Elsevier, vol. 204(C), pages 182-199.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:plo:pone00:0307086. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: plosone (email available below). General contact details of provider: https://journals.plos.org/plosone/ .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.